Immunosurveillance in clinical cancer management

CA A Cancer Journal for Clinicians, Journal Year: 2023, Volume and Issue: 74(2), P. 187 - 202

Published: Oct. 25, 2023

The progression of cancer involves a critical step in which malignant cells escape from control by the immune system. Antineoplastic agents are particularly efficient when they succeed restoring such (immunosurveillance) or at least establish an equilibrium state that slows down disease progression. This is true not only for immunotherapies, as checkpoint inhibitors (ICIs), but also conventional chemotherapy, targeted anticancer agents, and radiation therapy. Thus, therapeutics stress kill while provoking tumor-targeting response, referred to immunogenic cell death, useful combination with ICIs. Modern oncology regimens increasingly using combinations, chemoimmunotherapy, well combinations multiple However, latter generally associated severe side effects compared single-agent Of note, success these combinatorial strategies against locally advanced metastatic cancers now spurring successful attempts move them past postoperative (adjuvant) setting preoperative (neoadjuvant) setting, even patients operable cancers. Here, authors critically discuss importance immunosurveillance modern clinical management.

Language: Английский

---

Clinical and translational attributes of immune-related adverse events

Nature Cancer, Journal Year: 2024, Volume and Issue: 5(4), P. 557 - 571

Published: Feb. 15, 2024

Language: Английский

---

Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms

Autoimmunity Reviews, Journal Year: 2024, Volume and Issue: 23(7-8), P. 103589 - 103589

Published: July 1, 2024

Language: Английский

---

Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study

Annals of Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

---

Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade

Neurology Neuroimmunology & Neuroinflammation, Journal Year: 2023, Volume and Issue: 11(1)

Published: Oct. 26, 2023

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but come with immune-related adverse events (irAEs) that provide a novel challenge for treating physicians. Neuromuscular irAEs, including myositis, myasthenia gravis (MG), and demyelinating polyradiculoneuropathy, lead to significant morbidity mortality.

Language: Английский

---

Current Treatment and Immunomodulation Strategies in Acute Myocarditis

Journal of Cardiovascular Pharmacology, Journal Year: 2024, Volume and Issue: 83(5), P. 364 - 376

Published: Feb. 9, 2024

Myocarditis is an inflammatory disease of the myocardium characterized by a great heterogeneity presentation and evolution. Treatment myocarditis often supportive, evidence for immunosuppression scarce debated. Conventional treatment based on clinical presentation, ranging from conservative to advanced mechanical assist devices. In this setting, immunomodulation therapies are mostly reserved patients presenting with major syndromes. review, we will summarize current strategies conventional immunosuppressive treatments acute myocarditis.

Language: Английский

---

Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies

Clinical and Translational Medicine, Journal Year: 2024, Volume and Issue: 14(3)

Published: March 1, 2024

Abstract The emergence of immune checkpoint inhibitors (ICIs) has heralded a transformative era in the therapeutic landscape non‐small cell lung cancer (NSCLC). While ICIs have demonstrated clinical efficacy portion patients with NSCLC, these treatments concurrently precipitate spectrum immune‐related adverse events (irAEs), encompassing mild to severe manifestations, collectively posing risk significant organ damage. Consequently, there exists an imperative augment our comprehension pathophysiological underpinnings irAEs and formulate more efficacious preventive ameliorative strategies. In this comprehensive review, we delineate presentation organ‐specific NSCLC provide in‐depth analysis recent advancements understanding mechanisms driving ICI‐induced toxicity. Furthermore, discuss potential strategies targets for ameliorating irAEs. Ultimately, review aims furnish valuable insights guide further research endeavours context patients.

Language: Английский

---

Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression

Rheumatic Disease Clinics of North America, Journal Year: 2024, Volume and Issue: 50(2), P. 147 - 159

Published: Feb. 23, 2024

Language: Английский

---

Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy

Expert Review of Clinical Immunology, Journal Year: 2024, Volume and Issue: 20(8), P. 873 - 893

Published: Feb. 24, 2024

The advent of immune checkpoint inhibitors (ICIs) in cancer treatment has marked a transformative era, albeit tempered by immune-related adverse events (irAEs), including those impacting the musculoskeletal system. lack precise epidemiologic data on rheumatic irAEs is attributed to factors such as potential underrecognition, underreporting clinical trials, and tendency overlook manifestations without immediate life-threatening implications, further complicating determination accurate incidence rates, while complete understanding mechanisms driving remains elusive.

Language: Английский

---

Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity

Journal for ImmunoTherapy of Cancer, Journal Year: 2024, Volume and Issue: 12(3), P. e008482 - e008482

Published: March 1, 2024

Background Immune checkpoint inhibitors (ICIs) have improved outcomes and extended patient survival in several tumor types. However, ICIs often induce immune-related adverse events (irAEs) that warrant therapy cessation, thereby limiting the overall effectiveness of this class therapeutic agents. Currently, available therapies used to treat irAEs might also blunt antitumor activity ICI themselves. Therefore, there is an urgent need identify treatments potential be administered alongside optimize their use. Methods Using a translationally relevant murine model anti-PD-1 anti-CTLA-4 antibodies-induced irAEs, we compared safety efficacy prednisolone, anti-IL-6, anti-TNFɑ, anti-IL-25 (IL-17E), anti-IL-17RA (the receptor for IL-25) administration prevent reduce size. Results While all interventions were adequate inhibit onset pneumonitis hepatitis, treatment with or antibodies exerted additional activity. Mechanistically, IL-25/IL-17RA blockade reduced number organ-infiltrating lymphocytes. Conclusion These findings suggest may serve as target when treating ICI-responsive tumors, allowing better control while suppressing toxicities.

Language: Английский

---